NEFL and myeloid sarcoma: Serum multi-protein biomarker profiles based on proteomic multiplex immunoassay improve the prediction of real-world MS disability status beyond clinical profile alone or clinical profile plus single protein biomarker (e.g. NfL or GFAP), reaching clinically actionable performance.